Introduction
============

Interferon-beta (IFN-beta) is a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Multiple sclerosis (MS) is the most frequent inflammatory demyelinating disease of the central nervous system, usually affecting young adults, most frequently females (F:M ratio 2--3:1). The aetiology of the disease remains unknown, whereas the pathogenesis is most probably autoimmune. Despite the well-known efficacy and long-term tolerability of IFN-beta, a growing number of reports have recently associated long-term IFN-beta therapy with the development of systemic adverse effects.

Common side effects of IFN-based therapy are acute (influenza-like symptoms, fever, chills, myalgias, arthralgias, headache), sub-acute and chronic (fatigue, anorexia, general wasting). Complications associated with the administration of IFNs can affect nervous, haematopoietic, cardiovascular, endocrine and gastrointestinal systems. Clinical symptoms of autoimmune involvement and renal toxicity have also been described.

In preclinical surveys and in clinical trials, IFN-beta renal side effects were not infrequently reported but usually limited to mild proteinuria (rarely exceeding 1 g/24 h) in 15--20% of patients, increased enzymuria (indicating tubular injury), mild abnormalities in urinalysis, mild azotaemia and transient increase in serum creatinine \[[@sfw143-B1], [@sfw143-B2]\].

Different types of renal toxicity have been associated with IFN therapy: podocytopathies, immune-mediated glomerulonephritis, acute tubular necrosis, chronic tubulo-interstitial nephritis (acute and chronic) or thrombotic microangiopathy (TMA) \[[@sfw143-B3]\]. The incidence of renal complications remains undetermined, and the causal link between IFN and TMA is still underestimated.

TMA is a rare but severe disorder characterized by thrombotic occlusion of the microcirculation that causes consumptive thrombocytopenia, microangiopathic haemolytic anaemia and signs of ischaemic damage in different organs. Two processes dominate the sequence of pathological events: (i) damage of the endothelium and its activation, resulting in intravascular thrombosis; and (ii) platelet aggregation. Both of these events cause vascular obstruction and vasoconstriction and ultimately precipitation of distal ischaemia. Clinically, there may be different entities indicated as TMA-associated syndromes. Thrombotic thrombocytopenic purpura (TTP) and haemolytic uremic syndrome (HUS) represent the two most frequent causes of TMA. Secondary forms of TMA can be observed in association with drugs, connective tissue diseases, malignancies, transplantation, pregnancy, infections and other factors.

An extensive list of drugs has been associated with TMA \[[@sfw143-B4], [@sfw143-B5]\]. The first case of TMA associated with IFN-alpha was reported in 1993 \[[@sfw143-B6]\], and the first case associated with IFN-beta was reported in 1998 \[[@sfw143-B7]\]. Since then, 24 cases of IFN-beta related TMA have been reported in the literature, mostly as individual case reports. Recently, a direct causal effect has been suggested linking TMA with IFN-alpha \[[@sfw143-B8]\] and IFN-beta \[[@sfw143-B9]\].

The prognosis of drug-related TMA and particularly IFN-related TMA is particularly severe. It is generally characterized by fulminant presentation, even after years of well-tolerated treatment with IFN-beta, with severe clinical course, poor response to therapy and bad renal prognosis. Treatment has usually been IFN withdrawal and then plasma exchange (PE) and corticosteroids.

Eculizumab is a humanized monoclonal antibody inhibiting C5 activation, a critical effector mechanism in several types of TMA. Approved as first-line treatment for atypical HUS (aHUS), eculizumab was initially reported efficacious in cases that were refractory to plasma therapy and/or relapsing.

Here we report three cases of TMA in patients on IFN-beta, who did not respond to conventional therapy for TMA and who were successfully managed with eculizumab-based treatments.

Materials and methods
=====================

We describe three cases of IFN-beta-induced TMA diagnosed by our Nephrology Department between 2010 and 2015 in MS patients. The patients were regularly followed up at the Multiple Sclerosis Centre of the Department of Neurosciences, at the Careggi University Hospital, Florence.

Information on MS, including age at onset, duration of the disease, type of IFN treatment, concomitant medications, physical examination and disability levels at the time of the diagnosis of TMA, laboratory and clinical data were retrieved from medical records.

We also reviewed the IFN-related TMA cases reported in the literature.

A PubMed search was conducted using the medical subject headings terms: 'thrombotic microangiopathy', 'multiple sclerosis', 'haemolytic uremic syndrome', 'thrombotic thrombocytopenic purpura' and 'beta-interferon'.

Articles describing renal TMA cases in patients exposed to IFN-beta treatment were included. We excluded cases in which other possible aetiologic factors or triggers of TMA were present.

Ethical approval
----------------

This article does not contain any studies with human participants or animals performed by any of the authors.

Results
=======

Between 2010 and 2015, three cases of IFN-beta-induced TMA were diagnosed and followed by our Nephrology Department. All of the them were part of a cohort of 1988 patients regularly followed by the Multiple Sclerosis Centre of our hospital, of whom 913 were treated with IFN-beta: 441 with subcutaneous IFN-beta 1a (Rebif^®^), 322 with intramuscular IFN-beta 1a (Avonex^®^) and 150 with subcutaneous IFN-beta 1b (Betaferon^®^).

Our three cases are young patients with MS who developed TMA after a prolonged treatment with subcutaneous IFN-beta-1a (44 µg thrice weekly), which was effective in controlling neurological symptoms. Anti-IFN antibodies were negative in all of them.

Patients had normal renal function until a few weeks before admission, with silent medical history except for the RRMS. Immunological tests \[cryoglobulins, anti-nuclear antibody (ANA), anti-dsDNA, ANCA, anti-phospholipid antibodies, complement levels\] as well as infectious disease tests \[hepatitis B virus, hepatitis C virus, human immunodeficiency virus, cytomegalovirus, Epstein--Barr virus, parvovirus B19, *Escherichia coli* serotype O157:H7) and cancer markers were normal for all the patients.

All the patients presented with marked asthenia, severe high blood pressure (BP), acute kidney injury (AKI) and proteinuria in the absence of purpura, microscopic haematuria or leucocyturia.

Case 1 is a 46-year-old Caucasian female diagnosed with RRMS in 1994, and treated with IFN-beta-1a (Rebif^®^) since 1996 with good response and no complications, except for mild leukopenia and skin nodules in the injection sites. In May 2011, she referred to the Emergency Department due to the onset of severe headache, epigastric discomfort and profound weakness. On admission, severe arterial hypertension (250/130 mmHg) was detected and a laboratory workup compatible with TMA was evident (Table [1](#sfw143-T1){ref-type="table"}). The patient was transferred to the Nephrology ward where haemodialysis was initiated due to the severe AKI and anuria. Echocardiogram showed second-degree diastolic dysfunction, mild to moderate pulmonary hypertension and a good systolic function. Subsequent tests, carried out for suspected TMA, showed no mutations in complement genes and normal ADAMTS-13 activity. Despite IFN withdrawal, intravenous corticosteroids and 18 sessions of PE, the severe renal failure persisted with only a transient haematological response (Figure [1](#sfw143-F1){ref-type="fig"}). PE was discontinued and eculizumab was started at a dose of 900 mg intravenously for 4 weeks. At discharge the patient was still anuric, on dialysis with suboptimal BP control, but normal haematological values, despite eculizumab maintenance dosing of 1200 mg infused every 2 weeks. Not suspecting a pathogenic effect IFN-beta was reintroduced, but after 1 month it was suspected to be the causative factor for the TMA and was definitively withdrawn. The patient continued with eculizumab, with slow and progressive improvement of renal function, and after 5 months dialysis was permanently discontinued (Figure [1](#sfw143-F1){ref-type="fig"}). Four and a half years after the clinical onset, the patient is still under eculizumab therapy and she reports good health and has had no further recurrences of MS. She regained kidney function and remains out of dialysis \[chronic kidney disease (CKD) stage 4\], her BP is in good control with three anti-hypertensive drugs, there is no proteinuria and no signs of TMA. Table 1Laboratory findings in the three cases at admissionCase 1Case 2Case 3Age (years)463234SexFFMCreatinine (mg/dL)2.22.152.97Urea (g/L)1.011.28UrinalysisNo microhaematuriaNo microhaematuriaMicrohaematuria, glycosuria24 h proteinuria (g)1.54.91.32Hb (g/dL)6.98.06.3Platelet (per mm^3^)43 00019 00073 000PT, APTT, antithrombin, D-dimerNormal rangeNormal rangeNormal rangeLactate dehydrogenase (U/L)123019291840Coombs testNegativeNegativeNegativeHaptoglobineUndetectableUndetectableUndetectableSchistocytes on peripheral blood smear (%)753ADAMTS-13 (%) (ref. 50 -- 150%)905289Anti-CFH antibodiesNegativeNegativeNegativeComplement gene mutation analysisNegative (CFH, CFHR1-R3, MCP, CFI, CFB)Non-pathogenic heterozygous deletion CFHR1-R3   (negative CFH, MCP, CFI and CFB)Non-pathogenic heterozygous MCP mutation   (negative CFH, CFHR1-R3, CFI and CFB)[^1]

![Effect of eculizumab and IFN withdrawal on kidney function in three patients with TMA. Changes in renal function in the three cases since presentation of TMA. Blue arrow: definite discontinuation of IFN-beta from this timepoint; orange bar: period of PE; green bar: period of eculizumab therapy; yellow bar: corticosteroids.](sfw143f1){#sfw143-F1}

Case 2 is a 32-year-old Caucasian female diagnosed with RRMS in 2002 and treated with IFN-beta-1a (Rebif^®^) since then. IFN-beta had generally allowed good clinical control of the disease activity. In December 2013, she was hospitalized for dyspnoea associated with tachycardia and hypertension (170/100 mmHg). Echocardiogram showed hypertensive heart disease (interventricular septum 13 mm) with preserved systolic function (ejection fraction 60%). Her laboratory workup on admission (Table [1](#sfw143-T1){ref-type="table"}) showed severe thrombocytopenia, microangiopathic haemolytic anaemia, AKI and nephrotic-range proteinuria. The clinical and laboratory findings were compatible with the diagnosis of TMA. Complement gene mutation analysis showed a heterozygous deletion of CFHR1-R3, an alteration described as non-pathogenic in aHUS. PE with cryo-poor fresh frozen plasma was initiated immediately on a daily basis and then on an alternate-day regime, without any appreciable effect on intravascular haemolysis. She received a total of nine sessions of PE with poor response to treatment, as evidenced by progressive thrombocytopenia with lactate dehydrogenase and creatinine values persistently elevated. Moreover, during the first week, daily blood transfusions were required in order to maintain haemoglobin levels above 8 g/dL. Suspecting an IFN-related TMA, IFN-beta was discontinued and eculizumab therapy was then started. The patient was given intravenous (IV) eculizumab 900 mg weekly for 4 weeks, followed by 1200 mg 1 week later as the fifth dose and then every 2 weeks thereafter. The underlying microangiopathic process has gradually turned off, with slow but progressive improvement in kidney function (Figure [1](#sfw143-F1){ref-type="fig"}).

Two months later the patient was hospitalized for left leg weakness, and prescribed three pulses of methylprednisolone and oral prednisone, with rapid tapering. She has since been neurologically stable for over 1 year without steroids. Two and a half years after eculizumab initiation, the patient remains well, with persistent CKD (plasma creatinine 1.65 mg/dL; CKD stage 3), proteinuria 0.85 g/24 h, well-controlled BP with four anti-hypertensive drugs, and no signs of TMA.

Case 3 is a 34-year-old Caucasian man who developed RRMS in 1999 following the appearance of diplopia and right upper limb paraesthesias. In 2001, treatment with IFN-beta-1a (Rebif^®^) was started with good clinical control of the disease. In May 2015, he developed blurred vision, severe hypertension (205/115 mmHg), palpitations and tinnitus. Laboratory tests performed on arrival at the emergency unit were compatible with TMA (Table [1](#sfw143-T1){ref-type="table"}). TTP was ruled out by measuring ADAMTS 13 activity. Genetic analysis identified a heterozygous MCP mutation in the exon 11, p.Ala353Val(c.1058C \> T), previously reported in aHUS but with unknown pathogenic role. IFN treatment was stopped, and the patient was treated with daily PE for a total of eight sessions, until complete normalization of the haematological parameters. However, there was no complete renal function recovery, and a kidney biopsy was performed. Histological evaluation showed endothelial swelling and thickening of the capillary wall due to sub-endothelial expansion. Eculizumab treatment was then started. After about 10 months of treatment, laboratory tests showed a gradual improvement of renal function without clinical or laboratory signs of TMA recurrence (Figure [1](#sfw143-F1){ref-type="fig"}). The patient is still on therapy with eculizumab, maintaining stable renal function (CKD stage 2) and good BP control.

Discussion
==========

The case reports we present, together with the 24 reported in the literature (Table [2](#sfw143-T2){ref-type="table"}), suggest a causal relationship between IFN-beta treatment and TMA, hindering the hypothesis of a fortuitous association. This study enables us to delineate several peculiarities of this association. Table 2Cases of TMA occurring in MS patients treated with IFN-beta reported in the literatureAuthorPatient (sex, age in years)Exposure to IFN-betaClinical presentationLaboratory analysisComplement mutations/ADAMTS13 activityTherapy in addition to withdrawal of IFN-beta and anti-hypertensive drugsOutcomeNerrant \[[@sfw143-B10]\]F, 387 monthsBP 190/110 mmHg,PRESAKIno complement mutations, normal ADAMTS13PE, steroids per osESRDBroughton \[[@sfw143-B11]\]F, 538 years Betaseron®mild/severe hypertension, headacheAKI, proteinuria, haematuria----CKDMahe \[[@sfw143-B12]\]F, 385 yearsBP 180/130 mmHgAKIno complement mutations--stage 4 CKDMahe (FPD)NA, 585 yearssevere hypertensionAKI--PE, steroidsCKDMahe (FPD)NA, 661 yearhypertension------remissionMahe (FPD)NA, 52\>3 yearshypertensionAKIADAMTS13 deficitPECKDMahe (FPD)NA, 556 years----Ab-anti-ADAMTS13PE, steroids, RTXremissionMahe (FPD)NA, 3810 years------PE, steroidsNAOrvain \[[@sfw143-B13]\]M, 524 yearsBP 185/114 mmHgMHTAKI, haematuria, proteinuria 1.6 g/24 hANA 1:1280no complement mutationsanti-ADAMTS13 IgGPE, steroids 1 mg/kg/day, RTXESRDVosoughi \[[@sfw143-B9]\]M, 5214 years Betaseron®BP 203/123 mmHgMHT, seizuresAKI, no proteinuria--PEESRDVosoughi \[[@sfw143-B9]\]F, 4112 years Rebif®BP 231/150 mmHgMHT, headache, seizures, PRESno AKI, subnephrotic-range proteinuria,   microhaematuria----recoveredRubin \[[@sfw143-B14]\]F, 4110 yearsBP 220/140 mmHgMHT, PRESAKI, haematuria, proteinuria 1.35 g/24 h----remissionLarochelle \[[@sfw143-B15]\]F, 3414 monthsBP 195/120 mmHgMHT, headache, confusion, left hemiparesisARDSno AKI--PE, IV steroids, vincristine, RTXDeathLarochelle \[[@sfw143-B15]\]F, 4711 yearsBP 187/107 mmHgMHT, headacheAKI, mild proteinuria--PE, IV steroidsstage 4 CKDLarochelle \[[@sfw143-B15]\]F, 415 yearsBP 170/80 mmHgheadache, confusion, seizures, PRESAKI--PE, steroids per os, RTXESRDAzkune Calle \[[@sfw143-B16]\]M, 369 years IFN-beta-1asevere hypertensionheart failurepsychosisno AKI--PE, steroidsrecoveredCapobianco \[[@sfw143-B17]\]F, 2213 years IFN-beta-1achronic TMAmild hypertensionno AKI, proteinuria 1.2 g/24h, haematuria,  sarcoid-like lung disease----remissionLi Cavoli \[[@sfw143-B18]\]F, 363 monthssevere hypertensionAKI--PE, steroids (IV and per os)ESRDOlea \[[@sfw143-B19]\]F, 375 monthsBP 205/110 mmHgAKI, no haematuria, subnephrotic-range proteinuriano complement mutationssteroids 1 mg/kg/dayrecoveredHunt \[[@sfw143-B20]\]NA8 yearsBP 217/122 mmHgMHT, neurologic signsAKIno complement mutations, normal ADAMTS13NAESRDHunt \[[@sfw143-B20]\]NA6 yearsBP 192/112 mmHgMHT, neurologic signsAKIno complement mutations, normal ADAMTS13NAESRDHunt \[[@sfw143-B20]\]NA10 yearsBP 248/142 mmHgMHT, neurologic signsAKIno complement mutations, normal ADAMTS13NArecoveredHunt \[[@sfw143-B20]\]NA6 yearsBP 185/133 mmHgAKIno complement mutations, normal ADAMTS13NAESRDSerrano \[[@sfw143-B21]\]M, 509 years IFN-beta-1bheadache, lipothymia, visual lossAKI--PE, steroidsremissionCase 1F, 4615 yearsBP 250/130 mmHgMHT, headache, diastolic heart dysfunctionAKI, subnephrotic-range proteinuriano complement mutations, normal ADAMTS13PE, steroids, eculizumabstage 4 CKDCase 2F, 3211 yearsBP 170/100 mmHgMHT, left ventricular hypertrophyAKI, nephrotic-range proteinuriano complement mutations, heterozygous CFHR1-R3 deletion, normal ADAMTS13PE, eculizumabstage 3 CKDCase 3M, 3514 yearsBP 205/115 mmHgMHT, visual loss, tinnitus, headacheAKI, subnephrotic-range proteinuria, microhaematuriaheterozygous MCP mutation, normal ADAMTS13PE, eculizumabstage 2 CKD[^2]

The onset of TMA occurred after a mean of 7 years of IFN-beta therapy. Only 6 out of 27 patients had a drug exposure \<4 years, while 10 out of 27 patients had an exposure ≥ 10 years. Our three cases, as well as those described in the literature, indicate that long-term IFN therapy can induce late-onset TMA, suggesting that the development of renal lesions may be the result of a cumulative effect in renal and systemic microvessels.

In all the eight published cases reporting the results of genetic analysis, no mutations of complement factors were identified. In two cases, anti-ADAMTS13 IgG, the synthesis of which may have been favoured by IFN-beta treatment, were described. In support of this theory and in support of the immunogenicity of IFN \[[@sfw143-B22]\], there are several case reports describing acquired anti-ADAMTS13 IgG after IFN-alpha therapy.

In our cases, case 1 had no identified mutations, case 2 showed a heterozygous deletion CFHR1-R3, which is a polymorphism often associated with anti-CFH antibodies in aHUS, that were absent in this patient, and case 3 showed a heterozygous MCP mutation p.Ala353Val(c.1058C \> T). This mutation has been previously described in three children with aHUS, but the pathological role is still unclear, because all those patients had other risk factors or triggers of aHUS. The 3-year-old boy described by Davin *et al.* \[[@sfw143-B23]\] had several at-risk polymorphisms of MCP and CFH, which may have enhanced the pathogenic role of the MCP mutation. The child described by Bouts *et al.* \[[@sfw143-B24]\] had methylmalonic aciduria and homocystinuria secondary to cobalamin CblC disorder, which was considered the real cause of aHUS. The 9-year-old girl described by Banks *et al.* \[[@sfw143-B25]\] was diagnosed with a focal segmental glomerulosclerosis 1 year before developing aHUS. It is well known that different types of glomerulopathies may trigger aHUS with different mechanisms, frequently when associated with mutations or risk haplotypes for regulators of the alternative complement pathway \[[@sfw143-B26]\]. In the three mentioned cases, as in our patient, the mutation of MCP could predispose to aHUS, but a trigger is probably necessary, which in this case was the treatment with IFN-beta.

Genetic analysis of complement factors, as well as ADAMTS-13 levels and ADAMTS-13 inhibitors, should be performed in patients with IFN-related TMA. This may prove useful in the interpretation of the response to therapy and in driving the maintenance regimen.

The clinical presentation of IFN-related TMA is usually very severe and the renal prognosis is often poor.

When considering all the cases of IFN-beta-induced TMA, in published reports and herein, 85% presented with AKI, generally associated with sub-nephrotic proteinuria and mild or absent microhaematuria. Of these, 42% evolved towards end-stage renal disease (ESRD), 37% to advanced degree CKD, while only 21% recovered, often with no *restitutio ad integrum* and with persistent hypertension or proteinuria.

All published cases of IFN-beta-induced TMA had high BP, reported as severe hypertension (65%) or even malignant hypertension (MHT) (25%). This is particularly interesting since the US Food and Drug Administration reported arterial hypertension to occur rarely (0.4--5%) in patients treated with Rebif^®^ or Betaseron^®^. All the patients had fulminant presentation of the disease characterized by severe or MHT developed after years of well-tolerated treatment with IFN-beta. Moreover, hypertension often persisted after TMA resolution.

Malignant hypertension is defined as severe hypertension accompanied by ischaemic failure of one or more organs (kidney, cardiac hypertrophy, hypertensive encephalopathy) \[[@sfw143-B27]\].

Our three patients had severe hypertension, ischaemic damage of the kidneys, cardiac hypertrophy and hypertensive encephalopathy, which can be redefined as MHT-induced TMA secondary to IFN-beta.

Neurological involvement has been described in the acute phase in 17--55% of aHUS and in 100% of TTP cases. In patients with IFN-related-TMA, neurological involvement was frequent (70% of cases). The most common presenting symptom was severe headache, but seizures, confusion, focal deficits (paresis, hemiparesis), psychosis and visual loss were also described.

In about 25% of patients with neurological symptoms described in the literature, magnetic resonance imaging (MRI) documented cerebral lesions compatible with posterior reversible encephalopathy syndrome (PRES). The presence of PRES in the course of TMA has often been described, generally with uncontrolled hypertension and other factors like severe hypoproteinaemia, hypocalcaemia, high haematocrit or pulse methylprednisolone; characteristic presenting symptoms were headache, dimness of vision or cortical blindness, seizures and altered mentation. Unfortunately, cerebral MRI has not been performed in our patients at onset.

Despite treatment with PE, steroids or rituximab, renal dysfunction progressed in some patients, and the prognosis was generally poor.

Our patients and almost all the cases reviewed in the literature had normal renal function and urinalyses prior to IFN-beta therapy. Pre-existing hypertension was reported only in a few patients.

Conventional approaches to managing this entity, such as withdrawal of the suspected offending agent and/or PE, obtained limited improvement, with high rates of renal failure.

Eculizumab has been registered for the treatment of aHUS due to mutations in complement factors of the alternative pathway, but it also appears to be effective in the treatment of several secondary forms of TMA, e.g. pregnancy, haematopoietic stem cell transplantation, systemic lupus erythematosus and catastrophic antiphospholipid syndrome.

From a review of the literature, there are several described cases in which eculizumab was prescribed for drug-induced TMA that were refractory to conventional therapies. Eculizumab has been used with remarkable effectiveness for TMA secondary to therapy with gemcitabine \[[@sfw143-B28], [@sfw143-B29]\], cisplatin \[[@sfw143-B30]\] and forms of *de novo* TMA after kidney transplantation associated with calcineurin inhibitors \[[@sfw143-B31], [@sfw143-B32]\].

In MHT-induced TMA, it was demonstrated in rats that activation of renin--angiotensin system leads to angiotensin II-induced damage and complement activation \[[@sfw143-B33]\]. We could speculate that this may be the pathophysiological rationale regarding the effectiveness of eculizumab in our patients.

To our knowledge, we report the first three cases of IFN-related TMA treated with eculizumab showing a strikingly favourable effect on renal recovery. All of them responded with progressive clinical and renal improvement, allowing dialysis discontinuation, without recurrence of TMA during a long-term follow-up.

Despite the favourable adverse event profile of eculizumab, the very high cost of the drug and the scarceness of comparative studies on its long-term effectiveness and safety do not allow us to recommend the use of eculizumab as first-line strategy for IFN-beta induced TMA. We decided to start eculizumab after a mean of 12 PE (range 8--18) sessions, due to the severity of renal involvement despite partial haematological improvement.

There is also a need for a better understanding on the strategy to taper or withdraw eculizumab once it has been initiated. In our experience, we decided not to stop eculizumab considering the severity of renal involvement, the genetic abnormalities potentially predisposing to a recurrence of disease and the extremely favourable effect as a single agent on the course of MS, which is now object of further analysis.

In conclusion, TMA can occur in MS patients treated with IFN-beta, and these observations should prompt the neurologist to vigilance on this rare complication. Even after years of well-tolerated therapy, new onset of headache, hypertension or renal disease should be carefully evaluated since early diagnosis may improve clinical outcomes. The clinical presentation of IFN-related TMA is usually severe and the renal prognosis is often poor. Once it is suspected, interruption of IFN treatment is warranted while PE or eculizumab therapy is still a matter of debate. In our experience, after a run of unsuccessful PE, all three patients had a very favourable effect on TMA response and renal function with eculizumab therapy.

Conflict of interest statement
==============================

M.A., C.L.C., L.C., G.A., S.F., M.P.A. and E.E.M. declare no conflicts of interest with respect to the research, authorship and/or publication of this article. The authors declare that the results presented in this paper have not been published previously, in whole or part.

[^1]: PT, prothrombin time; APTT, activated partial thromboplastin time.
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